Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Comparing the obesity drugs

Increasing competition is the name of the game in drug development - a boon to patients, but an added layer of complexity for investors. The obesity field is a case in point. Until a few months ago, no new products had shown up in the armamentarium in years. But it's now likely that there will shortly be three: Interneuron Pharmaceuticals Inc.'s Redux dexfenfluramine, Knoll Pharmaceutical Co.'s Meridia sibutramine hydrochloride monohydrate, and Roche Laboratories' Xenical orlistat.

To help keep the players straight, the following is

Read the full 838 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers